Background: Matrine is one of the major alkaloids extracted from Sophora flavescens and has been used clinically for breast cancer with notable therapeutic efficacy in China. However, the mechanisms are still largely unknown. Methods: Cell viability was analyzed by MTT assay. After MCF-7 cells were treated with matrine for 48h, apoptosis was detected by flow cytometry, TUNEL assay and transmission electron microscopy, and the cell cycle distribution was also analyzed by flow cytometry. Further, the expression of PTEN, pAkt, Akt, pBad, Bad, p21 /WAF1/CIP1 , and p27 . Conclusion: Our study unraveled, for the first time, the ability of matrine to suppress breast cancer growth and elucidated the miR-21/PTEN/Akt pathway as a signaling mechanism for the anti-cancer action of matrine. Our findings also reinforce the notion that miRNAs can act as mediators of the therapeutic efficacy of natural medicines.
Introduction
Breast cancer is the most common malignancy and the leading cause of cancer death in women worldwide. There were about 1, 383, 500 new female breast cancer cases and 458, 400 of the total cancer deaths in 2008 [1] . Many patients especially with metastatic breast cancer must accept chemotherapy, such as anthracyclines and taxanes, which made patients encounter cumulative toxicity and additional tolerability problems [2] . Even more, most patients eventually develop resistance to chemotherapy, which frequently results in subsequent recurrence and metastasis.
Accumulating evidence suggests that natural agents open up a new avenue for successful treatment of cancers, especially by combining with conventional therapeutics [3] . Matrine is one of the effective monomers found in Sophora �lavescens. Its chemical formula is C 15 H 24 N 2 O. Matrine has long been used for the treatment of viral hepatitis, cardiac arrhythmia, and skin in�lammations [4] . It has been well documented that matrine inhibits growth and proliferation of various cancer cells through inducing apoptosis and cell cycle arrest [5] [6] [7] . Recent observations showed that matrine and its compounds inhibits proliferation, migration, and metastasis of breast cancer both in vitro and in vivo [8] [9] [10] , and were used as adjuvant therapy in China to improve the 5-year survival rate and life quality as well as immune functions of patients with breast cancer. However, little is known about the mechanisms underlying the therapeutic effects of matrine.
MicroRNAs (miRNAs) play important roles in the development of various types of cancers [11, 12] . MiRNA-21 (miR-21), as the most overexpressed miRNA in the vast majority of cancers, targets many important tumor suppressors to promote breast cancer growth, proliferation, migration, and metastasis [13, 14] . PTEN (phosphatase and tensin homolog, deleted on chromosome ten), as one of the target genes of miR-21 [15] , is a dual lipid and protein phosphatase that can dephosphorylate its downstream targets. Mutation of PTEN has been observed in about 5% of primary breast cancer and loss of expression rate is as high as 48% associated with a poor prognosis. Inactivation of PTEN leads to loss of its lipid phosphatase activity and accumulation of phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ), resulting in phosphorylation of Akt [16] . As a result, on one hand, inactivation of PTEN stimulates cell cycle progression and proliferation by down-regulating p21 /WAF1/CIP1 and p27 /KIP1 ; on the other hand, it prevents cancer cells from apoptosis by inhibiting apoptotic pathways [17, 18] . It appears that the miR-21/PTEN/Akt signaling pathway plays a critical role in tumorigenesis. It is not known, however, whether the anti-cancer effects of matrine are related to this pathway.
In view of the established anti-breast-cancer effects of matrine and the tumorigenic role of the miR-21/PTEN/Akt pathway in breast cancer, we proposed that matrine may inhibit breast cancer growth via the miR-21/PTEN/Akt pathway. This study was designed to test this hypothesis.
Materials and Methods

Materials
Matrine (purity >95%) was purchased from Kangjiu Chemical Co, China, and was dissolved in physiological saline to prepare a 20 mM stock solution which was stored at 4°C in the dark.
Cell culture
Human breast cancer cell line MCF-7 was purchased from Shanghai cell bank of Chinese Academy of Sciences (Shanghai, China). Cells were cultured in BPMI 1640 (Hyclone, USA) supplemented with 10% fetal bovine serum (Hyclone, USA) at 37°C in a humidi�ied atmosphere of 95% air and 5% CO 2 . /ml (0.2 ml/well) for 12 h. After exposure to matrine for 24, 48 and 72 hours, respectively, 20 µl methyl thiazolyl tetrazolium (MTT) solution (5 mg/ml) was added to each well and cells were incubated for another 4h. The formazan crystals were dissolved in 150 µl dimethylsulfoxide (DMSO) and the absorbance of samples was measured at 490 nm by a microplate reader (Model 3550, Bio-Rad Laboratories, CA). All experiments were performed in triplicate for three times.
Cell apoptosis by �low cytometry MCF-7 cells were collected after they had been treated with matrine at 0 (control), 0.4 mM (M1 group), 0.8 mM (M2 group) for 48h, and then washed twice with cold PBS. The cells were resuspended in 500 µl binding buffer at a concentration of 10 6 /ml and then mixed with 10 µl Annexin V (Beijing Biosea Biotechnology, CO.LTD, China) for 15 min in the dark at room temperature (RT), followed by the addition of 5 µl PI (Beijing Biosea Biotechnology, CO.LTD, China). After incubation at RT in the dark for 5 min, samples were analyzed by a FACSAria �low cytometry (BD Biosciences, San Jose, CA, USA).
TUNEL assay
TUNEL assay was carried out according to the manufacturer's protocol (In Situ Cell Death Detection Kit, POD, Roche, Germany). Brie�ly, MCF-7 cells were �ixed in 4% paraformaldehyde in PBS after treatment with matrine at 0, 0.4, or 0.8 mM for 48h, then washed with PBS three times followed by 3% H 2 O 2 in methanol for 10 min at RT. Next, cells on slides were incubated with 0.1% triton X-100 in 0.1% sodium citrate for 2 min on ice. Finally, cells were incubated with TUNEL reaction mixture for 1h, followed by DAPI for 5 min, at RT in the dark. Cells were analyzed by a �luorescence microscope (Eclipse 80I, Nikon, Tokyo, JP).
Examination of cell ultrastructure by transmission electron microscopy
After treatment with matrine at 0, or 0.8 mM for 48h, MCF-7 cells were �ixed in 2.5% glutaraldehyde overnight at 4 o C. The cells were then post-�ixed with 1% osmium tetraoxide for 2h, washed in PBS, and progressively dehydrated in a 10% graded series of 50%-100% ethanol and propylene oxide. The embedded blocks were cut into ultrathin sections with a microtome and stained with saturated uranyl followed by lead citrate. The ultrastructure of cells were examined by a transmission electron microscope (Hitachi H-7650, Tokyo, Japan), as previously described in detail [19] .
Cell cycle analysis by �low cytometry
After starvation in the serum-free medium for 12h, MCF-7 cells were treated with matrine at 0, 0.4, and 0.8 mM for 48h in BPMI 1640 supplemented with 10% fetal bovine serum. The cells were incubated with RNAse (Sigma, USA) and PI (Sigma, USA) [20] , and the DNA content was determined on a FACSCalibur system (BD Biosciences, San Jose, CA, USA) by using ModFitLT V3.2.1. To provide valid quantitative data, 10 5 individual cells were analyzed in each experiment.
Quanti�ication of miR-21
Total RNA was extracted from MCF-7 cells by TRIzol ® Reagent (Invitrogen, USA) following the manufacturer's protocol. MiR-21 levels were measured using the mirVana TM qRT-PCR miRNA Detection Kit (Ambion, USA) described as elsewhere [21] . Primers for real-time PCR were 5'-GGGGTAGCTTATCAGACTGATG-3' (miR-21 forward) and 5'-TGTCGTGGAGCGGCAATTG-3' (miR-21 reverse). Variations in expression of miR-21 between different RNA samples were calculated after normalization to U6.
Transfection of miRNAs MCF-7 cells were transfected with miR-21 mimics using X-treme (Roche, Germany) following the manufacturer's protocol. After 48h transfection, the expression of PTEN protein was measured by Western blot.
Western blot
Western blot analysis was carried out as described elsewhere [21] . Cells were washed with cold PBS and lysed in lysis buffer (western blot lysate: protease inhibitor cocktail=100:1). The concentration of proteins was determined by BCA Protein Assay Kit. The samples were electrophoresed in 12% SDS-PAGE gels. After electrophoresis, gels were transferred to nitrocellulose membranes by electroblotting and blocked in 5% nonfat milk in PBS at RT for 2h. The primary antibodies including anti-PTEN (Cell Signaling,
Results
Matrine inhibits breast cancer cells growth
The growth of breast cancer cell line MCF-7 was inhibited, as determined by MTT assay, after cells had been treated with matrine at 0.1, 0.2, 0.4, 0.8, and 1.6 mM for 24h, 48h, and 72h, respectively. It was found that matrine inhibited the growth of MCF-7 cells in a concentration-and time-dependent manner with an IC 50 (48h) of ~0.8 mM (Fig. 1) .
Matrine induces apoptosis in breast cancer cells
We used three different approaches, �low cytometry, TUNEL assay and electron microscopy, to examine the effects of matrine on MCF-7 cell apoptosis. As shown in Figure  2 , matrine induced signi�icant apoptotic cell death in MCF-7 cells. Measurements from our �low cytometry experiments indicated that matrine at concentrations of 0.4 and 0.8 mM caused 13.98 ± 0.98% and 25.6 ± 4.8% apoptotic cell death, respectively ( Fig. 2A & 2B) . TUNEL assay for chromosomal fragmentation yielded the results in support of above data: matrine remarkably increased the number of TUNEL-positive cells or apoptotic cells (Fig. 2C) . Transmission electron microscopic examination showed severe shrinking of cell morphology, nuclear fragmentation and apoptotic bodies in the presence of matrine in MCF-7 cells (Fig. 2D) .
Matrine induces cell cycle arrest at G 1 /S phase in breast cancer cells
Effects of matrine on cell cycle distribution were analyzed by �low cytometry in MCF-7 cells. The cells were found 63.96 ± 0.67% in G 1 phase, 23.53 ± 1.13% in S phase and 12.51 ± 0.78% in G 2 phase under control conditions (Fig. 3A) . After being treated with matrine at 0.8 mM for 48h, the number of cells in G 1 phase was increased to 84.62 ± 1.55% (P<0.001), 
Discussion
In the present study, we demonstrate that matrine induces apoptotic cell death and cell cycle arrest likely via downregulating miR-21 to alter the expression and activities of PTEN/Akt and the downstream molecules in MCF-7 human breast cancer cells. Our �indings uncovered the miR-21/PTEN/Akt signaling pathway as a novel mechanism by which natural agents like matrine produce anti-cancer effects.
Several reports have demonstrated that matrine inhibits cancer cell growth and proliferation by inducing apoptosis and cell cycle arrest in various types of tumors [5] [6] [7] 22] . Our data reinforce this point by showing that the ability of matrine to inhibit MCF-7 cells growth by at least partially inducing apoptosis and cell cycle arrest, suggesting that matrine could be used for the treatment of breast cancer. Previous studies have reported that matrine is able to up-regulate proapoptotic proteins including BH3 only proteins (Bim, Puma, Bad, Bik), Bok, Bak and Bax, and inhibit expression of anti-apoptotic proteins like Bcl-2 and Bcl-xl [5, 8, 23] . Our study indicates the miR-21/PTEN/Akt pathway as an alternative mechanism underlying the effects of matrine.
Interestingly, miR-21 is one of the most anomaly and commonly increased miRNAs in cancer, and plays important roles in cancer growth, proliferation, migration, and metastasis by targeting PTEN, PDCD4, Spry1 etc, or by up-regulating proteins like Bcl-2 indirectly [13] [14] [15] 24] . It was demonstrated that anti-miR-21 suppressed the growth and proliferation of MCF-7 cells in vitro and in vivo [13, 14] . PTEN is an important downstream target of miR-21 [15] , and overexpression of PTEN in a tetracycline-controlled inducible system induces apoptosis and blocks cell cycle progression in MCF-7 cells [17] . Besides, ectopic expression of PTEN suppresses tumorigenicity and cell growth through apoptosis, G 1 cell cycle arrest or both [17, 18, 25, 26] . However, matched analysis of breast tissues from normal and invasive ductal carcinoma indicated that there is no clear inverse correlation between miR-21 and PTEN [27] . We found that matrine inhibited the expression of miR-21 in MCF-7 cells to induce overexpression of PTEN and subsequently inactivate Akt, which likely activated Bad to trigger intrinsic apoptotic cascades [28] . The possible mechanisms by which matrine produces anti-cancer effects in MCF-7 is illustrated in Figure 6 . Based upon our hypothesis, Bad might be dephosphorylated when pAkt is inhibited, and is released through interacting with anti-apoptotic Bcl-2 family members. In our study, miR-21 was transfected in MCF-7 and found that PTEN was down-regulated signi�icantly, but had no effect on Bcl-2 (data was not shown), which may result from overexpression of endogenous miR-21 in MCF-7 cells. It was demonstrated that matrine induced apoptosis without in�luence on the total and phosphorylation of Bad in gastric cancer [5] , indicating that matrine may induce apoptosis in a cell speci�ic manner.
It is well known that p21 /WAF1/CIP1 is one of universal cyclin-CDK inhibitors that inhibit all cyclin-CDK complexes by its N-terminal homologous sequences to induce cell cycle arrest at G 1 , S, or G 2 phase [29] . Although p21 /WAF1/CIP1 -null mice develop normally, they were more susceptible to tumors caused by chemical agents and irradiation [30, 31] . Importantly, p21 / WAF1/CIP1 is reported as a transcriptional target of p53 after DNA damage and is regulated through p53 dependent or independent pathways to induce apoptosis [29] . On the other hand, accumulating studies indicated that loss of functional p27 /KIP1 plays an important role in tumorigenesis and development of human cancers [32] [33] [34] . During cell cycle progression the expression of p27 /KIP1 was changed and was highest in senescence, but it was reduced during G 1 and S phase [35] . In accordance with previous studies, our data showed that overexpression of PTEN can up-regulate p21 /WAF1/CIP1 and p27 /KIP1 by dephophorylating Akt.
